{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:48:27Z","timestamp":1790390907680,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences (MUMS)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ejps.2015.08.011","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T11:33:59Z","timestamp":1440070439000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma"],"prefix":"10.1016","volume":"80","author":[{"given":"Manouchehr","family":"Teymouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Farzaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Golmohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvan","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2015.08.011_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2015.08.011_bb0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2015.08.011_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08982109409037057","article-title":"Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes","volume":"4","author":"Bolotin","year":"1994","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2015.08.011_bb0020","first-page":"124","article-title":"A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia","volume":"31","author":"Boranic","year":"1979","journal-title":"Biomedicine"},{"key":"10.1016\/j.ejps.2015.08.011_bb0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijpharm.2014.09.009","article-title":"Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor","volume":"475","author":"Chen","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"5088","key":"10.1016\/j.ejps.2015.08.011_bb0030","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","article-title":"Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line","volume":"258","author":"Cole","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ejps.2015.08.011_bb0035","first-page":"1829","article-title":"Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2015.08.011_bb0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2015.08.011_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2015.08.011_bb0050","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/BF02535544","article-title":"Metabolism of ether phospholipids and analogs in neoplastic cells","volume":"22","author":"Fleer","year":"1987","journal-title":"Lipids"},{"key":"10.1016\/j.ejps.2015.08.011_bb0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0026-895X(25)10149-1","article-title":"Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells","volume":"45","author":"Fornari","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0060","unstructured":"Gabizon, A.A., Barenholz, Y., 2010. Method for drug loading in liposomes. Google Patents."},{"key":"10.1016\/j.ejps.2015.08.011_bb0065","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejps.2015.08.011_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejps.2015.08.011_bb0085","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/ja8065557","article-title":"Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties","volume":"130","author":"Huang","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2015.08.011_bb0080","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1002\/anie.200900111","article-title":"Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery","volume":"48","author":"Huang","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2015.08.011_bb0090","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.91.17.8302","article-title":"Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase","volume":"91","author":"Huber","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2015.08.011_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tox.2004.12.003","article-title":"Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats: the effects of vitamin E and catechin","volume":"209","author":"Kalender","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ejps.2015.08.011_bb0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00685563","article-title":"Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine","volume":"34","author":"Kaufmann-Kolle","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2007.10.009","article-title":"Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release","volume":"125","author":"Lindner","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2015.08.011_bb0110","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0115","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.tiv.2013.06.010","article-title":"Effect of miltefosine on erythrocytes","volume":"27","author":"Munoz","year":"2013","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejps.2015.08.011_bb0120","first-page":"337","article-title":"The histological antitumor effect and side effects of preoperative chemotherapy for patients with oral squamous cell carcinoma\u2013comparison between low-dose and high-dose CDDP regimens. Gan to kagaku ryoho","volume":"28","author":"Nakazawa","year":"2001","journal-title":"Cancer Chemother."},{"key":"10.1016\/j.ejps.2015.08.011_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0169-409X(01)00233-2","article-title":"The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors","volume":"53","author":"Needham","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.08.011_bb0130","first-page":"51","article-title":"Pharmacokinetics (PK), tumor localization (TL), and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma (AIDS-KS)","author":"Northfelt","year":"1993","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0135","first-page":"20.21. 21","article-title":"B16 as a mouse model for human melanoma","author":"Overwijk","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biopha.2005.09.001","article-title":"A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines","volume":"60","author":"Papagiannaros","year":"2006","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2015.08.011_bb0145","first-page":"129","article-title":"Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice","volume":"20","author":"Papagiannaros","year":"2006","journal-title":"In Vivo"},{"key":"10.1016\/j.ejps.2015.08.011_bb0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0155","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2015.08.011_bb0160","first-page":"876","article-title":"Synthesis and cytotoxicity of novel pyrido [1, 2-e] purines on multidrug resistant human MCF7 cells","volume":"54","author":"Pinguet","year":"1999","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2015.08.011_bb0165","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1054\/bjoc.2001.1776","article-title":"MDR1 causes resistance to the antitumour drug miltefosine","volume":"84","author":"Rybczynska","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2015.08.011_bb0170","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-05-1566","article-title":"Preclinical efficacy of the camptothecin-polymer conjugate it-101 in multiple cancer models","volume":"12","author":"Schluep","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2015.08.011_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF03042191","article-title":"Effect of selenium on the side effect profile of adjuvant chemotherapy\/radiotherapy in patients with breast carcinoma. Design for a clinical study","volume":"94","author":"Schumacher","year":"1999","journal-title":"Med. Klin. (Munich)"},{"key":"10.1016\/j.ejps.2015.08.011_bb0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nucmedbio.2009.02.004","article-title":"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model","volume":"36","author":"Soundararajan","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0185","series-title":"Radiocontrast Agents","author":"Sovak","year":"1987"},{"key":"10.1016\/j.ejps.2015.08.011_bb0190","series-title":"Trypan Blue Exclusion Test of Cell Viability, Current Protocols in Immunology","author":"Strober","year":"2001"},{"key":"10.1016\/j.ejps.2015.08.011_bb0195","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2015.08.011_bb0200","first-page":"4730","article-title":"Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors","volume":"42","author":"Tsuruo","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2015.08.011_bb0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000420840","article-title":"Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients","volume":"34","author":"Unger","year":"1992","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.ejps.2015.08.011_bb0210","first-page":"67","article-title":"Intertriginous eruption is a benign side effect of high-dose chemotherapy","volume":"143","author":"Webber","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejps.2015.08.011_bb0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2015.08.011_bb0220","first-page":"45a","article-title":"Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx\/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer","author":"Wigler","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715003668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715003668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:45:36Z","timestamp":1760528736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098715003668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":44,"alternative-id":["S0928098715003668"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2015.08.011","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2015.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}